Table 1.
Main characteristics of the studies included.
| Study | Study design | Study period | Study region | ICI treatment | Cancer Type | Sample size | Age (years) | Gender (male/ female) |
Outcome | NOS |
|---|---|---|---|---|---|---|---|---|---|---|
| Yekedüz et al. 2022 (17) | R | – | Turkey | Nivolumab | RCC | 152 | 60(54-67)b | 117/35 | PIV (OS, PFS) | 7 |
| Corti et al. 2021 (20) | R | 05/2014-06/2020 | Italy | Anti-PD-(L)1 with or without anti-CTLA-4 antibodies | CRC | 163 | 50/113d | 90/73 | PIV (OS, PFS) | 7 |
| Qi et al. 2023 (15) | P | 03/2019-03/2022 | China | Pembrolizumab | ESCC | 51 | 62(39-75)a | 44/7 | PIV (PFS) | 6 |
| Sooi et al. 2022 (18) | R | 01/2015-01/2022 | Singapore | ICIs | NSCLC | 230 | 63e | 161/69 | PIV (OS, PFS) | 8 |
| Mesti et al. 2022 | R | 01/2018-12/2020 | Slovenia | Pembrolizumab, Nivolumab, Ipilimumab | Melanoma | 129 | 66(30-85)a | 84/53 | PIV (OS, PFS) | 7 |
| Guven et al. 2021 (12) | R | 06/2016-06/2020 | Turkey | Anti-PD-(L)1 antibodies | Pan-cancer | 120 | 61(54-67)b | 86/34 | PIV, PILE (OS, PFS) | 7 |
| Zeng et al. 2021 (1) | R | – | China | Atezolizumab | SCLC | 53 | 26/27c | 34/19 | PIV, PILE (OS, PFS) | 6 |
| Zeng et al. 2021 (2) | R | 01/2015-02/2021 | China | Anti-PD-(L)1 antibodies | SCLC | 84 | 37/47c | 75/9 | PIV, PILE (OS, PFS) | 7 |
amedians (ranges); bmedians (interquartile range); c≥ 65 vs. < 65; d≥ 70 vs. < 70; emedians; R, retrospective study; P, prospective study; ICIs, immune checkpoint inhibitors; ; PD-(L)1, programmed cell death (ligand)-1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; RCC, renal cell carcinoma; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; OS, overall survival; PFS, progression-free survival; PIV, pan-immune-inflammation value.